“Advancements in Genetic Diagnostics and Personalized Treatment Approaches”
- A significant and accelerating trend in the Asia-Pacific multiple hereditary exostosis (MHE) market is the growing integration of advanced genetic diagnostic tools and the emergence of personalized treatment protocols tailored to the specific needs of pediatric patients with skeletal dysplasias. This trend is improving early detection and enabling targeted intervention strategies
- For instance, next-generation sequencing (NGS) technologies are increasingly used in countries such as Japan and China to identify EXT1 and EXT2 gene mutations, allowing clinicians to diagnose MHE early and accurately. Genetic counseling is also becoming a common practice in specialized orthopedic and pediatric clinics
- The rising adoption of non-invasive imaging techniques, such as low-radiation CT and high-resolution MRI, enables better monitoring of exostoses progression and helps in surgical planning. Coupled with AI-powered radiological analysis, these tools offer more precise lesion tracking and treatment customization
- These diagnostic advancements, along with greater public health awareness campaigns and screening programs in urban centers, are fostering a shift toward proactive management of the disease rather than reactive surgical intervention only after complications arise
- Patient registries and cross-border collaborations are increasing across the region, with countries such as South Korea and Australia participating in rare disease networks that facilitate clinical research and data sharing on MHE. These initiatives help generate region-specific epidemiological insights and promote evidence-based care
- This growing focus on early-stage identification and personalized care is transforming the landscape of MHE treatment in Asia-Pacific, creating a platform for medical innovation and the delivery of patient-centric orthopedic solutions
